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Costs were estimated by the UNU-Casemix Group (UNU-CBG) system, a top-down
costing system developed by the United Nations University-International Institute
for Global Health and the National University of Malaysia. The above costing sys-
tem was used in the countries included in this study. An episode of inpatient care
for any condition was defined as all treatments provided by the hospital from the
time of admission until discharge. Length of stay and cost per acute episode of MI
were identified for analysis. Local currency costs were converted to 2012 US$.
RESULTS: The average length of stay for a mild, moderate and severe episode of
acute MI in Indonesia was 6.0, 8.3 and 13.8 days respectively, compared to 5.8, 7.5
and 9.2 days in Malaysia and 4.5, 7.1 and 10.2 days in the Philippines. The average
cost of mild, moderate and severe acute MI in these countries were US $1075, US
$1698 andUS $2450 in Indonesia, US $1264, US $1616 andUS $1999 inMalaysia, and
US $1220, US $1927 and US $2779 in the Philippines. CONCLUSIONS: Our results
show that length of stay and treatment cost for an episode of acute MI varied
between countries and increased with clinical severity. Differences may be due to
factors such as health systems and reimbursement mechanisms. In addition, we
found that the available cost data is useful for analysis of health care costs in South
East Asia.
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OBJECTIVES: In light of the medicare savings debate in the US and AMNOG reform
in Germany, we aim to compare average branded factory price and average annual
cost of treatment for amiodarone and propafenone, the two most commonly pre-
scribed drugs for the treatment of arrhythmia, across 6 countries (EU top 5 and US).
METHODS:A quantitative analysis was performed using the average factory prices
for each branded active pharmaceutical ingredient (API) from IHS PharmaOnline
International (POLI) and average annual treatment costs from IHS World Markets
Cardiovascular and Metabolic service (WMCVM). We used dosing monographs to
calculate the total average dosing to accommodate for regional differences in cur-
rent treatmentmodalities. RESULTS: In the United States, the average price permg
for amiodarone is $0.006 and average annual cost of treatment is $2326. In the
Germany, UK, Italy, Spain and France, the average price per mg for amiodarone is
€0.025, £0.003, €0.003, €0.001 and €0.001, and average annual cost of treatment is
€9216, £1147, €973, €492, €365, respectively. In the United States, the average price
per mg for propafenone is $0.014 and average annual cost of treatment is $3480. In
the Italy, Spain, Germany, and United Kingdom, the average price per mg for
propafenone is €0.003, €0.001, €0.0009, £0.0005, and, and average annual cost of
treatment is €751, €380, €231, £124, respectively. CONCLUSIONS: That the price and
cost of amiodarone treatment is the highest in Germany is notable given the recent
launch of AMNOG. Amiodarone is one of themost common comparator for cardio-
metabolic drugs and its high price could allow for higher prices for newer market
entrants. The relative high price and cost of propafenone treatment in the United
States gives credence to proponents of health care savings who argue for system-
atic overhaul of drug prices.
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OBJECTIVES: To describe the real-world clinical complications associated with ve-
nous thromboembolism (VTE) and quantify the incremental direct all-cause and
disease-specific health care utilization and costs associated with VTE.METHODS:
Health insurance claims between January 2004 and December 2008 from the
IMPACTdatabasewere used. Adult patientswith an indexVTE diagnosis (deep vein
thrombosis [DVT], pulmonary embolism [PE], or both) were matched 1:1 with con-
trol patients without VTE. Each patient’s observation period began on the date of
the index VTE or corresponding date for controls and ended on the earlier of 1 year
after the study index date, the health plan disenrollment date, or December 31,
2008. The proportion of patients with recurrent VTE requiring hospitalization or
post-thrombotic syndrome (PTS)was calculated. All-cause incremental health care
costs associated with VTE and disease-specific costs related to VTE complications
were also reported. RESULTS: The VTE and no-VTE cohorts (16,969 subjects in each
group) were well matched for age, gender, comorbidities, and VTE risk factors. The
index VTE event was DVT, PE, or both in 12,711, 2473, and 1785 patients, respec-
tively. The risks of recurrent VTE requiring hospitalization and PTS during the
1-year follow-up period were 3.6% and 6.2%, respectively. Patients with VTE had
significantly higher average yearly all-cause costs compared to no-VTE patients
(mean [SD]: $33,531 [$70,393] versus $17,590 [$42,011], cost difference$15,941; 95%
CI14,819–17,012). Disease-specific health care costs related to VTE complications
represented 18.3% ($2913 of $15,941) of the all-cause cost difference between the
two groups. CONCLUSIONS: In this large matched-cohort study, VTE was associ-
ated with a 3.6% risk of hospitalization due to recurrence and a 6.2% risk of PTS at
1 year. VTE was also associated with significant health care cost burden—disease-
specific costs related to VTE complications represented nearly one-fifth of the in-
cremental all-cause costs associated with VTE.
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OBJECTIVES: To estimate the 1-year direct and indirect costs of ischemic stroke in
Chinese patients with atrial fibrillation (AF).METHODS:A cost-of-illness studywas
conducted through hospital chart review and a patient follow up survey. Costs
were estimated from the societal perspective. Three hundred hospital charts from
12 tier-3 hospitals and 6 tier-2 hospitals in 6 cities across China were randomly
selected and reviewed for cost of stroke during hospitalization from patients dis-
charged from January, 2009 to December, 2010 (discharge diagnosis of both, isch-
emic stroke and AF). Of those, 50 patients were followed up to collect the long-term
direct and indirect costs related to ischemic stroke in the year following discharge.
RESULTS:We report here results from two hospitals (N30): patients had a mean
age of 75 years and mean length of stay of 16 days (95%CI [14, 19]). Females
accounted for 43%. The mean time interval between stroke onset and hospitaliza-
tion was 24 hours (95%CI [14, 33]). The cohort scored on average 3 points (95%CI
[2, 4]) on the CHA2DS2-VASc, indicating a high risk of stroke considering patient
demographics and disease history. Average total 1-year costs of stroke manage-
mentwere estimated at 19,560.01 RMB (2010 costs; 4951.90US$), almost all ofwhich
was attributable to direct costs. Costs of inpatient care dominated direct costs,
representing 90.3% of the total direct costs. Average total costs during hospitaliza-
tion were estimated at 17,659.31 RMB (95%CI [13,538.39, 21,780.23]), 62.5% of
which was attributable to medication. CONCLUSIONS: The findings indicate that
ischemic stroke among AF patients are associated with high direct costs, imposing
a considerable burden on society. Hospital costs are the predominant contributor,
consistent with the current pattern of care in China, where patient care is usually
provided via hospitals.
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OBJECTIVES: To develop United States (US) cost model estimates for venous
thromboembolism (VTE), comprised of deep vein thrombosis (DVT) and pulmonary
embolism (PE). Total US costs were calculated as well as hospital-acquired, “pre-
ventable”, and indirect VTE costs.METHODS:A literature reviewwas performed to
determine VTE incidences, morbidity probabilities, case-fatality rates, and direct
medical and indirect costs. Indirect costs were derived from present value of life-
time earnings (PVLE) due to premature death. Two decision trees mapping PE and
DVT outcomes were developed, and cost models were constructed in Microsoft
Excel. The decision trees first contain primary VTE characteristics and outcomes:
hospital- or community-acquired; fatal versus non-fatal; readmission/recurrence
versus none; and instant versus non-instant death. Initially surviving patients are
at risk for associated morbidities: minor bleed; major bleed; heparin induced
thrombocytopenia; chronic thromboembolic pulmonary hypertension; post-
thrombotic syndrome; and resolution or no resolution of symptoms or death. The
average patient’s cost, the sum of each decision tree pathway’s probability-
weighted cost, weremultiplied by low and high annual PE and DVT incident events
to determine total cost ranges. All costs were adjusted to 2011 US dollars. Two
multi-way sensitivity analyses were conducted: one analysis has higher probabil-
ities and costs; the second introduces long term attack rates (LTAR), pooled inci-
dent and recurrent events, into the baseline and first multi-way sensitivity analy-
ses with only low VTE incidences. RESULTS: Annual US total base case (LTAR
sensitivity analysis), hospital-acquired, preventable, and indirect VTE costs range
from$13.4-27.0 ($15.3-34.3) billion, $8.9-18.0 ($10.2-25.3) billion, $4.5-14.0 ($5.1-12.7)
billion, and $4.5-9.8 ($5.6-11.7) billion, respectively. PE comprises the majority of
VTE costs. Indirect costs due to PVLE represent at least 33% of total VTE costs.
CONCLUSIONS: The United States could avoid substantial costs, morbidity and
mortality if effective VTE prophylactic strategies were implemented. This attain-
able goal would contribute to important health care reform.
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OBJECTIVES: Using longitudinal data, this study examined the determinants of
pharmaceutical expenditures for patients with hypertension, and the impact of
lifestyle andmarriage status changes on pharmaceutical expenditures.METHODS:
The longitudinal household components and the prescribedmedicine data ofMed-
ical Expenditure Panel Survey (MEPS) for year 2008 and 2009 were employed. Five
rounds of the survey were conducted for Panel 13 households between years 2008
and 2009. Only round 3 and round 5 surveys were used for this work because BMI
values were only included in these two rounds. I included individuals older than 18
years, not pregnant, with hypertension but no other comorbid conditions, andwho
had obtained a prescription for antihypertensive agents for essential hypertension
(ICD-9 code 401). The final panel data contained 1814 observations, among which
average agewas 53.65 years (SD13.49), the average age at the time of hypertension
diagnosis was 44.22 (SD13.43) years, 49.91% (SD0.50) were male. Ordinary Least
Square and Mixed Effect Model were employed to investigate the determinants of
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pharmaceutical expenditure for patients with hypertension. RESULTS: Pharma-
ceutical expenditures increased with age and the duration of hypertension. A
mixed effect model indicated that being widowed or separated significantly in-
creased pharmaceutical expenditures by $219.12 (P0.0001) and $206.84 (P0.0001)
respectively; the pharmaceutical expenditures decreases by $2.79 (P0.01) if BMI
decreased by 1 kg/m2 from survey round 3 to round 5. Pharmaceutical expenditures
decreased with family size and education level. Compared with the uninsured,
those with public insurance spent $208.33 (P0.0001) more, and those with private
insurance spent $121.01 (P0.0001)more on prescribed medicine for essential
hypertension. CONCLUSIONS: Age, duration of hypertension, marriage status,
BMI, type of insurance, and education were found as significant determinants of
pharmaceutical expenditures for patients with hypertension.
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OBJECTIVES: To investigate the association between blood pressure (BP) control
and healthcare utilization and costs in newly treated patientswith hypertension in
a managed care organization. METHODS: Patients who met the selection criteria
were identified from a healthcare organization during July 2005 – May 2008: 1) age
18; 2) 1 diagnosis of hypertension; 3) 1 prescription for hypertension; 4) con-
tinuously eligible with the organization 6 months before and 12 months after the
initiation of the antihypertensive agent(s) (index date); and 5) 2 blood pressure
(BP) readings with 1 at the index date, and another measured over 90 days of
receivingmedications. Patientswere classified into BP at goal vsersus BP not at goal
by the mean BP during 90 to 365 days after the index date. BP goal is defined as
140/90mmHg for hypertensive patientswithout diabetes, and130/80mmHg for
hypertensive patients with diabetes. Health care utilization and costs for the 12-
month post index date were compared between groups. RESULTS: We identified
1056 patients, themean age was 63 years old, and 54%were females. Overall, there
were 61% of the patients with BP at goal and 36% of the patients with comorbid
hypertension and diabetes met BP goal. The patients who met BP goal had higher
number of outpatient visits (19.0 vs. 14.0; p0.001), higher prescription fills (31.0 vs.
25.0; p0.001), and higher total costs ($7016 vs. $4628; p0.001) than those not at
goal. CONCLUSIONS: To achieve BP goal, physicians would have to follow-up with
patients frequently and emphasize the benefits ofmaintaining BP to goal. Although
the economic benefits of BP control is not immediately seen in the first year treat-
ment in this study, other studies have shown that long term control does prevent
the complications of hypertension, and demonstrate the long term economic ben-
efits. Additional research is warranted.
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OBJECTIVES: To analyze the structure of expenses associated with warfarin dose
adjustment and consequent international normalized ratio (INR) monitoring for
effective stroke prevention in patients with atrial fibrillation.METHODS: The pres-
ent study was designed as cost of illness analysis. Expenses associated with INR
monitoring and warfarin dose adjustment were calculated for four different cir-
cumstances: 1) for obligatorymedical insurance system according the current gen-
eral tariff agreement; 2) for patients managed in outpatient department of Univer-
sity hospital using prices for consultations and coagulation tests; 3) for those
controlling INR in commercial laboratory using their price list; and 4) for self-
monitored patients using costs for coagulomether and test strips purchasing.
RESULTS:Within the obligatory medical insurance system total expenses for war-
farin management accounted for 4058 Roubles/person per year, but share of ex-
penses for warfarin purchasingwas less than 1%; for patients treated in outpatient
department of University clinic that estimated for 13019 Roubles/person per year
and 0.03%; in the case of INR control in commercial laboratory – 18648 Roubles/
person per year and 0.02%; and for self-moniroring – from 40,405 Roubles/person
per year (0.01%) in the first year (that includes the fee for coagulomether purchas-
ing) to 7405 Roubles/person per year (0.05%) in consequent years respectively.
CONCLUSIONS: Regardless the strategy of INR control, concomitant expenses as-
sociated with warfarin dose adjustment and subsequent efficiency and safety
monitoring is more than 100-fold higher than the price of warfarin itself.
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OBJECTIVES:One of themajor complications aftermajor orthopedic surgery (OS) is
Venous Thromboembolism (VTE). VTE is an important condition not only because
of the potential long term complications to patients, but also the cost burden it
brings to the society. Unfortunately, no data readily exists showing the cost of VTE
prophylaxis (VTEp) in Turkey. Therefore, this study calculates the diagnosis and
treatment costs of VTEp aftermajor OS based on expert opinion.METHODS:Health
Economists of BayerTürk created a survey to a)determine the resources utilized in
diagnosis and treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism
(PE), b)establish the costs corresponding to potential complications of VTEp; intra
cerebral hemorrhages (ICH) and gastrointestinal bleeds (GIB) The survey was com-
pleted by the pioneers in Orthopedics and Traumatology, cardiovascular diseases,
hematology, gastroenterology, neurology and pulmonary diseases, based on daily
clinical practice and guidelines. An Expert Panel preceded the completion of sur-
veys, during which a consensus is reached. Based on the consensus, the costs of
VTEp are calculated from payer’s perspective. RESULTS: According to expert opin-
ion, there are approximately 20,000-30,000 TKR, 25,000-30,000 THR surgeries are
performed annually in Turkey. The major bleeding rates among these patients is
approximately 1%, half of them being ICH and the other half being GIB. Ddiagnosis
and treatment costs of VTEp and major bleeds calculated based on expert opinion
are: a)Diagnosis cost of DVT (PE): TL 33 (48) for inpatients and TL 126 (150) for
outpatients, b)Treatment cost of DVT (PE): TL 372 (1177) if hospitalization is re-
quired and TL 162 (757) if not, c)Diagnosis cost of ICH (GIB): TL 81 (192), d)Treatment
cost of ICH (GIB): TL 682 (537). CONCLUSIONS: This study displays the importance
of VTE prophylaxis. Diagnosis and treatment of VTE creates disease and cost bur-
den to the public and the society.
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OBJECTIVES:Orthopedic surgery presents a high risk of venous thromboembolism
(VTE). Without prophylaxis, between 41% and 85% of patients who undergo high-
risk orthopedic procedures develop deep vein thrombosis (DVT) and up to 10%
develop pulmonary embolism (PE). Furthermore, the economic burden of VTE is
perceived as substantially high in Colombia. Few data on the total economic bur-
den of DVT and PE associated to orthopedic surgery, however, is available in the
country. The objective of this study was to quantify the economic burden of DVT
and PE in the Colombian health care setting.METHODS:Delphi Panelmethodology
was used to estimate 2011 resource utilization associated with VTE treatment
events in patients undergoing hip and knee replacement. Delphi Panel contained
specialists from the private Colombian setting. Local available databases and pub-
lished literature was retrieved. Cost estimations (inpatient and outpatient costs,
acquisition costs, bleedings costs, intracranial hemorrhages and other associated
costs) considered the private perspective, using unit cost data from Seguro Obliga-
torio de Accidentes de Tránsito (SOAT). RESULTS: In Colombia the cost of hip
replacement surgery (in 2011USD)was estimated at USD $3182 and the cost of knee
replacement at USD$2942. Mean symptomatic PE costs for inpatients with hip
replacement was USD$6651 and DVT mean costs was USD$4061. Cost of treating
minor bleeding adverse events in patients with hip replacement, was estimated as
USD$4157 andmajor bleeding as USD$6171. Themean symptomatic PE costs (2011
US$) for inpatients with knee replacement was USD$6538 and DVTwas USD $3801.
Cost of treating minor bleeding adverse events in patients with knee replacement,
was estimated as USD$3931 andmajor bleeding as USD$5945. CONCLUSIONS: The
occurrence of VTE events related to orthopedic surgery can significantly impact
overall costs of orthopedic surgery in Colombia.
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OBJECTIVES: Deep vein thrombosis (DVT) and pulmonary embolism (PE) are clini-
cal manifestations of VTE that can occur with or without symptoms. A major risk
factor for VTE is orthopedic surgery. The economic burden of recurrent VTE asso-
ciated to hip and knee replacement is perceived as considerable high within the
Argentinean health care system; however, the data supporting this perception is
scarce. The objective of this study is to document the health care resource utiliza-
tion and costs associatedwith the care of VTEp and its complications related to hip
and knee replacement in Argentina. METHODS: Data regarding health care re-
sources associated with the treatment of VTE and major and minor bleeding was
estimated using Delphi panel methodology in 2011 (specialists from public and
private settings); locally available databases and published literature. Costs esti-
mations (inpatient and outpatient costs, acquisition costs, bleedings costs, intra-
cranial hemorrhages and other associated costs) considered a weighted average of
three different perspectives: 1) private; 2) public health care system; and 3) social
insurance. Costs are reported in 2011 USD. RESULTS: The estimated mean cost -if
events occur while hip replacement inpatient surgery- of treating symptomatic PE
is approximately USD$4510while the cost of DVTwas estimated inUSD $2904. Cost
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